Wishing you a healthy and happy Thanksgiving! We are grateful for our dedicated team and for the patients, caregivers, physicians, partners, and communities who inspire and support our mission to improve patients’ lives.
REGENXBIO
Biotechnology Research
Rockville, Maryland 44,735 followers
Seeking to improve lives through the curative potential of gene therapy.
About us
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.
- Website
-
https://www.regenxbio.com
External link for REGENXBIO
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Rockville, Maryland
- Type
- Public Company
- Founded
- 2008
- Specialties
- Biotechnology, Biopharmaceuticals, and Gene Therapy
Locations
-
Primary
Get directions
9804 Medical Center Dr
Rockville, Maryland 20850, US
Employees at REGENXBIO
Updates
-
Our CEO, Curran Simpson, recently joined BiotechTV to discuss how REGENXBIO is leading innovation in AAV gene therapy and to share his excitement for upcoming milestones across our pipeline of potential one-time therapies for patients with retinal and rare diseases. Listen here: https://lnkd.in/gbTQUTTe
-
Last weekend, our team participated in CureDuchenne’s Family Workshop in Boston. The event brought together local families, clinicians, researchers, and advocates to exchange knowledge, share resources, and inspire continued progress. We’re grateful to CureDuchenne for leading these important conversations.
#Boston showed up big this Saturday. Our CureDuchenne workshop brought together extraordinary families, the UMASS Duchenne Clinic team, and inspiring adults living with Duchenne who shared their journeys with powerful honesty and strength. Huge thanks to our generous sponsors—you make gatherings like this possible, and your impact reaches far beyond the room. 👉 Avidity Biosciences, Inc. Catalyst Pharmaceuticals, Inc. Edgewise Therapeutics Entrada Therapeutics ITF Therapeutics LLC NS Pharma, Inc. PTC Therapeutics, Inc. REGENXBIO Sarepta Therapeutics Find an upcoming workshop or event near you: https://lnkd.in/gpF-RgQk #DMD #Duchenne #CureDuchenne #CommunityMatters #RareDisease #MuscularDystrophy Debra Miller
-
This weekend, our team had the privilege of joining the Jett Foundation Family Workshop in Norfolk, VA. It was an inspiring day of connection among families, clinicians, and researchers working to improve the lives of those living with Duchenne. We’re grateful to the Jett Foundation for organizing this event to bring the local community together!
-
-
REGENXBIO reports third quarter 2025 financial results and operational highlights. Learn more: https://lnkd.in/exT_xep3
-
-
November is National Family Caregivers Month. These unsung heroes are incredible multitaskers and compassionate organizers, providing care, love, and support for those who need it most. At REGENXBIO, we’re working to deliver one-time treatments with the potential to reduce the treatment burden, helping ease the load for caregivers and patients, and change the way care is delivered for millions facing genetic or chronic diseases. Take a moment to recognize and thank a caregiver in your life!
-
-
November is Diabetes Awareness Month. Did you know that up to 1 in 4 people with diabetes have diabetic retinopathy, a leading cause of vision loss in adults? Early detection and treatment can help protect sight, yet only ~60% of people with diabetes get their recommended yearly eye exam. At REGENXBIO, we’re working to change the future of vision health by developing gene therapies with the potential to transform the standard of care for people with diabetic retinopathy with the ultimate goal of preserving their vision. #DiabetesAwarenessMonth #DiabeticRetinopathy
-
-
Today we announced the completion of enrollment in the AFFINITY DUCHENNE® pivotal trial of RGX-202, our differentiated investigational gene therapy for Duchenne, as well as progress towards our planned commercial launch. To support our potential accelerated approval plans and continued access to RGX-202 for patients, the confirmatory portion of the AFFINITY DUCHENNE study is open and enrolling. Learn more: https://lnkd.in/eKJR-Pd3
-